Diagnostic value of contrast-enhanced ultrasound in differentiating focal testicular lesions: A meta-analysis

doi:10.3969/j.issn.1004-583X.2024.05.001

Abstract

Abstract:

Objective To evaluate the diagnostic value of contrast-enhanced ultrasound (CEUS) in focal testicular lesions. Methods Relevant studies regarding CEUS in differentiating focal testicular lesions which reported from the establishment of the databases to August 10, 2023 were retrieved from databases including PubMed, EMBASE, Cochrane Library, Web of Science, China BioMedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Data and VIP Data. Eligible documents were conducted for data extraction, quality evaluation. RevMan 5.4, Meta disc1.4 and Stata15.0 were employed to analyze the diagnostic performance of CEUS for differentiating testicular lesions in tumor-like lesions and differentiation of benign and malignant. Results Thirteen original studies representing 712 lesions were included. Meta analysis showed that the pooled sensitivity, specificity, positive likelihood radio and negative likelihood ratio of CEUS for differentiating testicular neoplastic tumors in tumor-like lesions were 0.95(95%CI: 0.87-0.98), 0.84(95%CI: 0.73-0.91), 5.8(95%CI: 3.3-10.2), 0.06(95%CI: 0.02-0.17), respectively, and the area under the curve (AUC) for the summary receiver operating characteristic (SROC) was 0.94 (95%CI: 0.92-0.96). The pooled sensitivity, specificity, positive likelihood radio and negative likelihood ratio of CEUS for differentiating testicular lesions in differentiation of benign and malignant were 0.95(95%CI: 0.85-0.99), 0.81(95%CI: 0.65-0.90), 4.9 (95%CI: 2.5-9.6), 0.06(95%CI: 0.02-0.20), respectively, and the AUC for SROC was 0.96(95%CI: 0.94-0.97). Conclusion CEUS has a high diagnostic value for focal testicular lesions and can provide a reference for clinical diagnosis and treatment.

Key words: contrast-enhanced ultrasound, focal testicular lesions, neoplastic tumors and tumor-like lesions, benign and malignant neoplasms, Meta analysis

CLC Number:

R616.9

Gao Ming, Liu Hao, Yu Hang, Lin Lin, Zhang Zijie, Xiong Ying. Diagnostic value of contrast-enhanced ultrasound in differentiating focal testicular lesions: A meta-analysis[J]. Clinical Focus, 2024, 39(5): 389-395.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.05.001

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I5/389

Figures/Tables 10

References 21

[1]	Xue NY, Wang GY, Zhang SM, et al. The value of contrast-enhanced ultrasonography in differential diagnosis of primary testicular germ cell tumors and non-germ cell tumors over 50 years old[J]. Front Oncol, 2023, 13: 1090823.
[2]	Deininger S, Lusuardi L, Pallauf M, et al. The diagnostic value of the added mr imaging of the scrotum in the preoperative workup of sonographically indeterminate testicular lesions-A retrospective multicenter analysis[J]. Cancers, 2022, 14(15):1-13.
[3]	Corcioni B, Brandi N, Marasco G, et al. Multiparametric ultrasound for the diagnosis of Leydig cell tumours in non-palpable testicular lesions[J]. Andrology-US, 2022, 10(7):1387-1397. doi: 10.1111/andr.13233 pmid: 35842907
[4]	Withey SJ, Horsfield CJ, Prezzi D. Multiparametric ultrasound of nonpalpable focal testicular lesions[J]. Semin Ultrasound CT MR, 2020, 41(4):402-408. doi: S0887-2171(20)30040-8 pmid: 32620230
[5]	Bertolotto M, Muca M, Curro F, et al. Multiparametric US for scrotal diseases[J]. Abdom Radiol, 2018, 43(4):899-917.
[6]	Sidhu PS, Cantisani V, Dietrich CF, et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: Update 2017 (long version)[J]. Ultraschall Med, 2018, 39(2):e2-e44.
[7]	Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: A revised tool for quality assessment if diagnostic accuracy studies[J]. Ann Intern Med, 2011, 155(8):529-636. doi: 10.7326/0003-4819-155-8-201110180-00009 pmid: 22007046
[8]	Lock G, Schmidt C, Helmich F, et al. Early experience with contrast-enhanced ultrasound in the diagnosis of testicular masses: A feasibility study[J]. Urology, 2011, 77(5):1049-1053. doi: 10.1016/j.urology.2010.12.035 pmid: 21334049
[9]	Isidori AM, Pozza C, Gianfrilli D, et al. Differential diagnosis of nonpalpable testicular lesions: Qualitative and quantitative contrast-enhanced US of benign and malignant testicular tumors[J]. Radiology, 2014, 273(2):606-618. doi: 10.1148/radiol.14132718 pmid: 24968192
[10]	Schroder C, Lock G, Schmidt C, et al. Real-time elastography and contrast-enhanced ultrasonography in the evaluation of testicular masses: A comparative prospective study[J]. Ultrasound Med Biol, 2016, 42(8):1807-1815. doi: 10.1016/j.ultrasmedbio.2016.03.026 pmid: 27181687
[11]	Lung PFC, Fang C, Jaffer OS, et al. Vascularity of intra-testicular lesions: Inter-observer variation in the assessment of non-neoplastic versus neoplastic abnormalities after vascular enhancement with contrast-enhanced ultrasound[J]. Ultrasound Med Biol, 2020, 46(11):2956-2964. doi: S0301-5629(20)30344-6 pmid: 32863063
[12]	江鑫辉, 郑丽, 杜联芳, 等. 超声造影鉴别诊断睾丸肿瘤与肿瘤样病变的临床价值[J]. 临床超声医学杂志, 2021, 23(1):53-56.
[13]	Yu J, Jiang XH, Du LF, et al. Contrast-enhanced ultrasound as a valuable imaging modality for characterizing testicular lesions[J]. Asian J Androl, 2022, 24(2):201-206.
[14]	Xue NY, Zhang SM, Wang GY. The value of contrast-enhanced ultrasonography in the diagnosis of primary testicular non-neoplastic and neoplastic lesions in adults[J]. Bmc Urol, 2022, 22:1-12.
[15]	Liu H, Dong L, Xiang LH, et al. Multiparametric ultrasound for the assessment of testicular lesions with negative tumoral markers[J]. Asian J Androl, 2023, 25(1):50-57.
[16]	Auer T, Zordo TD, Dejaco C, et al. Value of multiparametric us in the assessment of intratesticular lesions[J]. Radiology, 2017, 285(2):640-649. doi: 10.1148/radiol.2017161373 pmid: 28628420
[17]	Lerchbaumer MH, Auer TA, Marticorena GS, et al. Diagnostic performance of contrast-enhanced ultrasound (CEUS) in testicular pathologies: Single-center results[J]. Clin Hemorheol Micro, 2019, 73(2):347-357.
[18]	Schwarze V, Marschner C, Sabel B, et al. Multiparametric ultrasonographic analysis of testicular tumors: A single-center experience in a collective of 49 patients[J]. Scand J Urol, 2020, 54(3):241-247. doi: 10.1080/21681805.2020.1765863 pmid: 32449437
[19]	Liu QP, Gong HL, Zhu H, et al. The application value of contrast-enhanced ultrasound in testicular occupied lesions[J]. Comput Math Method M, 2021, 2021:1-5.
[20]	李振东, 聂芳, 刘婷, 等. 多模态超声成像对睾丸良恶性病变的鉴别诊断价值[J]. 中华超声影像学杂志, 2023, 32(5):406-411.
[21]	Trinci M, Cirimele V, Ferrari R, et al. Diagnostic value of contrast enhanced ultrasound(CEUS) and comparison with color Doppler ultrasound and magnetic resonance in a case of scrotal trauma[J]. J Ultrasound, 2020, 23(2):189-194.

第一作者	发表年份	国家	研究类型	诊断标准	样本量	平均年龄 (岁)	病灶大小范围(cm)	TP (个)	FP (个)	FN (个)	TN (个)	纳入总病灶数(个)
Lock^[8]	2011	德国	前瞻性	病理	51	40.4±15.0	未报道	38	1	5	7	51
Isidori^[9]	2014	意大利	前瞻性	病理和临床	115	34.0	0.5-1.1	71^#/35^*	7^#/8^*	15^#/9^*	22^#/63^*	115
Schroder^[10]	2016	德国	前瞻性	病理	67	39.8	未报道	50	2	4	11	67
Lung^[11]	2020	英国	回顾性	病理和临床	86	39.0	0.2-6.0	44	13	2	32	91
江鑫辉^[12]	2021	中国	回顾性	病理	40	43.8±20.6	2.1-6.6	26	1	0	13	40
Yu^[13]	2022	中国	回顾性	病理	47	42.4±19.9	0.4-7.9	31	1	0	15	47
Xue^[14]	2022	中国	回顾性	病理	35	43.1±14.8	1.0-6.5	28^#/23^*	0^#/0^*	0^#/0^*	8^#/13^*	36
Liu^[15]	2023	中国	回顾性	病理和临床	79	45.9±16.1	0.9-4.4	34^#/19^*	6^#/14^*	4^#/1^*	23^#/33^*	67
Auer^[16]	2017	澳大利亚	回顾性	病理和临床	55	39.5±14.9	0.2-2.5	12	10	0	33	55
Lerchbaumer^[17]	2019	德国	回顾性	病理和临床	45	42.0	1.4-4.6	13	2	1	29	45
Schwarze^[18]	2020	德国	回顾性	病理	49	46.0	0.2-8.0	33	9	3	4	49
Liu^[19]	2021	中国	回顾性	病理和临床	9	38.0	0.8-5.2	5	1	0	3	9
李振东^[20]	2023	中国	回顾性	病理	40	36.5±15.9	0.4-8.0	16	6	0	18	40

第一作者	发表年份	国家	研究类型	诊断标准	样本量	平均年龄 (岁)	病灶大小范围(cm)	TP (个)	FP (个)	FN (个)	TN (个)	纳入总病灶数(个)
Lock^[8]	2011	德国	前瞻性	病理	51	40.4±15.0	未报道	38	1	5	7	51
Isidori^[9]	2014	意大利	前瞻性	病理和临床	115	34.0	0.5-1.1	71^#/35^*	7^#/8^*	15^#/9^*	22^#/63^*	115
Schroder^[10]	2016	德国	前瞻性	病理	67	39.8	未报道	50	2	4	11	67
Lung^[11]	2020	英国	回顾性	病理和临床	86	39.0	0.2-6.0	44	13	2	32	91
江鑫辉^[12]	2021	中国	回顾性	病理	40	43.8±20.6	2.1-6.6	26	1	0	13	40
Yu^[13]	2022	中国	回顾性	病理	47	42.4±19.9	0.4-7.9	31	1	0	15	47
Xue^[14]	2022	中国	回顾性	病理	35	43.1±14.8	1.0-6.5	28^#/23^*	0^#/0^*	0^#/0^*	8^#/13^*	36
Liu^[15]	2023	中国	回顾性	病理和临床	79	45.9±16.1	0.9-4.4	34^#/19^*	6^#/14^*	4^#/1^*	23^#/33^*	67
Auer^[16]	2017	澳大利亚	回顾性	病理和临床	55	39.5±14.9	0.2-2.5	12	10	0	33	55
Lerchbaumer^[17]	2019	德国	回顾性	病理和临床	45	42.0	1.4-4.6	13	2	1	29	45
Schwarze^[18]	2020	德国	回顾性	病理	49	46.0	0.2-8.0	33	9	3	4	49
Liu^[19]	2021	中国	回顾性	病理和临床	9	38.0	0.8-5.2	5	1	0	3	9
李振东^[20]	2023	中国	回顾性	病理	40	36.5±15.9	0.4-8.0	16	6	0	18	40